Metabolic syndrome components worsen lower urinary tract symptoms in women with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 3, 2010, Pages 1143-1150

  Tai, Huai Ching ^a,b   Chung, Shiu Dong ^a,b   Ho, Chen Hsun ^a   Tai, Tong Yuan ^a,c   Yang, Wei Shiung ^a,b   Tseng, Chin Hsiao ^a   Wu, Huey Peir ^a   Yu, Hong Jeng ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Taipei Jen Chi Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERACTIVE BLADDER; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; UROFLOWMETRY;

EID: 77749270919     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1492     Document Type: Article

References (33)

1. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino Sr RB, Wilson PW 2007 Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 30:1219-1225
2. Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y, Hirakata H, Iida M 2006 Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 48:383-391
3. Watanabe S, Yaginuma R, Ikejima K, Miyazaki A 2008 Liver diseases and metabolic syndrome. J Gastroenterol 43:509-518
4. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, Cavallo MG, Zalunardo B, Lirussi F, Alessandri C, Violi F 2005 Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 90:1578-1582
5. Esposito K, Giugliano F, Martedì E, Feola G, Marfella R, D'Armiento M, Giugliano D 2005 High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 29:1201-1203
6. Corona G, Mannucci E, Schulman C, Petrone L, Mansani R, Cilotti A, Balercia G, Chiarini V, Forti G, Maggi M 2006 Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol 50:595-604
7. Rohrmann S, Smit E, Giovannucci E, Platz EA 2005 Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes 29:310-316
8. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A 2007 The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51:199-206
9. Lawrence JM, Lukacz ES, Liu IL, Nager CW, Luber KM 2007 Pelvic floor disorders, diabetes, and obesity in women: findings from the Kaiser Permanente Continence Associated Risk Epidemiology Study. Diabetes Care 30:2536-2541
10. Kebapci N, Yenilmez A, Efe B, Entok E, Demirustu C 2007 Bladder dysfunction in type 2 diabetic patients. Neurourol Urodyn 26:814 -819
11. Yamaguchi C, Sakakibara R, Uchiyama T, Yamamoto T, Ito T, Liu Z, Awa Y, Yamamoto K, Nomura F, Yamanishi T, Hattori T 2007 Overactive bladder in diabetes: a peripheral or central mechanism? Neurourol Urodyn 26:807-813
12. Alexander CM, Landsman PB, Teutsch SM, Haffner SM 2003 Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP): NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANESIII participants age 50 years and older. Diabetes 52:1210-1214
13. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT 1992 The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148:1549-1557
14. Nixon A, Colman S, Sabounjian L, Sandage B, Schwiderski UE, Staskin DR, Zinner N 2005 A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174:604-607
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497
16. Yu HJ, Lee WC, Liu SP, Tai TY, Wu HP, Chen J 2004 Unrecognized voiding difficulty in female type 2 diabetic patients in the diabetes clinic: a prospective case-control study. Diabetes Care 27:988-989
17. Ueda T, Yoshimura N, Yoshida O 1997 Diabetic cystopathy: relationship to autonomic neuropathy detected by sympathetic skin response. J Urol 157:580-584
18. Yoshimura N, Chancellor MB, Andersson KE, Christ GJ 2005 Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int 95:733-738
19. Kaplan SA, Te AE, Blaivas JG 1995 Urodynamic findings in patients with diabetic cystopathy. J Urol 153:342-344
20. Menéndez V, Cofán F, Talbot-Wright R, Ricart MJ, Gutiérrez R, Carretero P 1996 Urodynamic evaluation in simultaneous insulin-dependent diabetes mellitus and end stage renal disease. J Urol 155:2001-2004
21. Ouslander JG 2004 Management of overactive bladder. N Engl J Med 350:786-799
22. Lee WC, Wu HP, Tai TY, Yu HJ, Chiang PH 2009 Investigation of urodynamic characteristics and bladder sensory function in the early stages of diabetic bladder dysfunction in women with type 2 diabetes. J Urol 181:198-203
23. Metascreen Writing Committee, Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A 2006 The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care 29:2701-2707
24. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L 2001 The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 44:1148-1154
25. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H 2005 The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 90:5698-5703
26. Grundy SM 2007 Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 92:399-404
27. Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J 2009 The metabolic syndrome and its traits as risk factors for subclinical atherosclerosis. J Clin Endocrinol Metab 94:2893-2899
28. Kozlowski R, Kershen RT, Siroky MB, Krane RJ, Azadzoi KM 2001 Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol 165:1019-1026
29. Azadzoi KM, Shinde VM, Tarcan T, Kozlowski R, Siroky MB 2003 Increased leukotriene and prostaglandin release, and overactivity in the chronically ischemic bladder. J Urol 169:1885-1891
30. Temml C, Obermayr R, Marszalek M, Rauchenwald M, Madersbacher S, Ponholzer A 2009 Are lower urinary tract symptoms influenced by metabolic syndrome? Urology 73:544-548
31. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA 2005 Erectile dysfunction and subsequent cardiovascular disease. JAMA 294:2996-3002
32. Scarpero HM, Fiske J, Xue X, Nitti VW 2003 American Urological Association Symptom Index for lower urinary tract symptoms in women: correlation with degree of bother and impact on quality of life. Urology 61:1118-1122
33. Okamura K, Nojiri Y, Osuga Y, Tange C 2009 Psychometric analysis of international prostate symptom score for female lower urinary tract symptoms. Urology 73:1199-1202